buserelin has been researched along with Prostatic Neoplasms in 309 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 197 (63.75) | 18.7374 |
| 1990's | 96 (31.07) | 18.2507 |
| 2000's | 13 (4.21) | 29.6817 |
| 2010's | 2 (0.65) | 24.3611 |
| 2020's | 1 (0.32) | 2.80 |
| Authors | Studies |
|---|---|
| Cicione, A; De Nunzio, C; Franco, A; Gravina, C; Grimaldi, MC; Guercio, A; Lombardo, R; Nacchia, A; Tema, G; Tubaro, A | 1 |
| Belanger, A; Chertin, B; Farkas, A; Fridmans, A; Hartman, H; Labrie, F; Spitz, IM | 1 |
| Brower, V | 1 |
| Cheung, P; Choo, R; Danjoux, C; Gardner, S; Loblaw, DA; Morton, G; Pearse, M; Szumacher, E | 2 |
| Fastovets, SV; Gafanov, PA; Kaprin, AD | 1 |
| Carsi, M; Iannazzo, S; Perachino, M; Pradelli, L | 1 |
| Hamm, J; Morris, WJ; Pickles, T; Schreiber, WE; Tyldesley, S | 1 |
| Flynn, A; Franklin, J; Hislop, J; McArdle, CA | 1 |
| Chander, S; Cheung, P; Choo, R; Danjoux, C; Deboer, G; Loblaw, A; Morton, G; Pearce, A; Szumacher, E; Woo, T | 1 |
| Bergman, R; Gez, E; Rozin, AP | 1 |
| Chander, S; Cheung, P; Choo, R; Danjoux, C; Deboer, G; Loblaw, A; Morton, G; Pearse, A; Szumacher, E; Woo, T | 1 |
| Barbara, AM; Fleshner, N; Gray, RE; Sinding, C; Trosztmer, C; Wassersug, RJ | 1 |
| Cury, FL; David, M; Duclos, M; Faria, SL; Freeman, CR; Gagnon, B; Rajan, R; Shenouda, G; Souhami, L; Tanguay, S | 1 |
| Petas, A; Pettersson, B; Sandow, J; Varenhorst, E | 1 |
| Bélanger, A; Dupont, A; Labrie, F | 1 |
| Adenauer, H; Borgmann, V; Hardt, W; Nagel, R; Schmidt-Gollwitzer, M | 1 |
| Sandow, J | 1 |
| Chadha, DR; Matroos, A | 1 |
| Kirby, JD; Perry, L; Rustin, MH; Waxman, J | 1 |
| Ahmed, SR; Blacklock, NJ; Grant, J; Howell, A; Shalet, SM | 1 |
| Beacock, C; Buck, AC; Griffiths, K; Peeling, WB; Turkes, A; Turkes, AO; Walker, KJ; Zwink, R | 1 |
| Bloom, SR; Dunlop, H; Griffin, S; Kerle, D; Williams, G | 1 |
| Allen, JM; Bloom, SR; Kerle, D; O'Shea, JP; Smith, C; Williams, G; Yeo, T | 1 |
| Allen, J; Bloom, SR; Doble, A; Kerle, D; Ware, H; Williams, G | 1 |
| Jacobi, GH; Wenderoth, UK | 3 |
| Besser, GM; Hendry, WF; Malpas, JS; Oliver, RT; Wass, JA; Waxman, JH; Whitfield, HN | 1 |
| Belanger, A; Cusan, L; Dupont, A; Fazekas, AT; Husson, JM; Labrie, F; Lefebvre, FA; Raynaud, JP | 1 |
| Faure, N; Fazekas, AT; Klioze, S; Koutsilieris, M; Lemay, A; Tolis, G; Yakabow, A | 1 |
| Belanger, A; Cusan, L; Dupont, A; Emond, JP; Fazekas, AT; Husson, JM; Laberge, JG; Labrie, F; Lefebvre, FA; Monfette, G; Raynaud, JP | 1 |
| Al-Abadi, H; Borgmann, V; Nagel, R; Schmidt-Gollwitzer, M | 2 |
| Koutsilieris, M; Tolis, G | 2 |
| Belanger, A; Dupont, A; Fazekas, AT; Gareau, J; Husson, JM; Labrie, F; Lacoursiere, Y; Monfette, G; Raynaud, JP; Sandow, J | 1 |
| Fazekas, AT; Koutsilieris, M; Patton, R; Tolis, G | 1 |
| Faure, N; Fazekas, AT; Jean, C; Laroche, B; Lemay, A; Plante, R; Robert, G; Roy, R; Thabet, M | 1 |
| Bary, P; Besser, GM; Hendry, WF; Malpas, JS; Oliver, RT; Wass, JA; Waxman, JH; Whitfield, HN | 1 |
| Waxman, J | 3 |
| Belanger, A; Dupont, A; Labrie, F; Lefebvre, FA; Raynaud, JP | 1 |
| Blankenstein, MA; de Jong, FH; Klijn, JG; Lamberts, SW | 1 |
| Bélanger, A; Dupont, A; Emond, J; Labrie, F; Monfette, G | 1 |
| Soloway, MS | 2 |
| Adenauer, H; Fazekas, AT; Klioze, S; Koutsilieris, M; Stellos, A; Tolis, G; Yakabow, A | 1 |
| Faure, N | 1 |
| Dufresne, M; Herrera, R; Koutsilieris, M; Martinez, A; Stellos, A; Tolis, G | 1 |
| Ackman, D; Comaru-Schally, AM; Fazekas, AT; Labrie, F; Mehta, A; Schally, AV; Stellos, A; Tolis, G | 1 |
| Bélanger, A; Faure, N; Gourdeau, Y; Labrie, F; Laroche, B; Lemay, A; Robert, G | 1 |
| Adenauer, H; Happ, J; Jacobi, GH; Krause, U; Wenderoth, UK | 1 |
| Belanger, A; Cusan, L; Dupont, A; Emond, JP; Fazekas, AT; Husson, JM; Laberge, JG; Labrie, F; Lacourciere, Y; Monfette, G; Raynaud, JP | 1 |
| Kojima, M; Ohe, H; Watanabe, H | 1 |
| Dondi, D; Garattini, E; Limonta, P; Marelli, MM; Moretti, RM; Motta, M | 1 |
| Baker, T; Docherty, A; Isenberg, D; Tickle, S; Wasan, H; Waxman, J | 1 |
| De Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, FH; Studer, UE; Sylvester, R | 1 |
| Castagnetti, G; Dotti, A; Ferrari, G; Ferrari, P; Pollastri, CA; Tavoni, F | 1 |
| Doré, JC; Fiet, J; Gô, AL; Ojasoo, T; Raynaud, JP | 1 |
| Aro, J; Hansson, E; Juusela, H; Permi, J; Ruutu, M | 1 |
| Kamoi, K; Kojima, M; Naya, Y; Ohe, H; Terasaki, T; Watanabe, H | 1 |
| Arrer, E; Frick, J; Jungwirth, A; Mack, D; Patsch, W | 1 |
| Bruun, E; Frimodt-Møller, C | 2 |
| Kawaoi, A; Komatsu, H; Maezawa, H; Ueno, A | 1 |
| de Voogt, H; Denis, L; Sylvester, RJ | 1 |
| de Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, FH; Studer, U; Sylvester, R | 1 |
| Cook, T; Sheridan, WP | 1 |
| Dondi, D; Limonta, P; Maggi, R; Moretti, RM; Motta, M | 1 |
| Debruyne, FM; Fernandez del Moral, P; Mulders, PF; Oosterhof, GO; Theeuwes, AG; van Berkel, HT | 1 |
| Matzkin, H; Soloway, MS | 1 |
| Carlström, K; Hasenson, M; Lundh, B; Pousette, A; Stege, R; Tribukait, B | 1 |
| Arkell, DG; Blackledge, GR; Dunn, JA; Emtage, LA; Lynch, TH; Wallace, DM; Waymont, B | 1 |
| Kennealey, GT; Vogelzang, NJ | 1 |
| Belmonte, P; Ciaccio, B; Dal Bo, V; Foladore, S; Franceschi, S; Francini, M; Lo Re, G; Monfardini, S; Talamini, R; Veronesi, A | 1 |
| Bunce, C | 1 |
| Schmeller, N | 1 |
| Davies, JH; Dearnaley, DP; Gelister, JS; Shearer, RJ | 1 |
| Höfler, H; Lax, S; Pummer, K; Radner, H; Wandschneider, G | 1 |
| Blom, JH; De Jong, FH; Kwekkeboom, DJ; Lamberts, SW; Schroeder, FH | 1 |
| Dundas, GS; Porter, AT; Venner, PM | 1 |
| Armitage, TG; Cooper, EH; Denis, L; Newling, DW; Richards, BR; Robinson, MR; Smith, PH; Sylvester, R | 1 |
| Banchini, A; Ceda, GP; Ceresini, G; Denti, L; Negro-Vilar, A; Valenti, G; Westel, WC | 1 |
| Chodak, GW; Kellman, H; Silver, RI; Straus, FH; Vogelzang, NJ | 1 |
| Chrisp, P; Goa, KL | 1 |
| Chaban, M; Denis, L; Mahler, C; Verhelst, J | 1 |
| Block, NL; Chodak, G; Gau, TC; Kennealey, G; Schellhammer, PF; Scott, M; Smith, JA; Soloway, MS; Vogelzang, NJ | 1 |
| Caplan, RJ; Chodak, GW; Smith, JA; Soloway, M; Vogelzang, NJ | 1 |
| Bono, A; Carneiro de Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R | 1 |
| al-Bussam, N; Citrin, DL; Gau, TC; Guinan, P; Kennealey, GT; Resnick, MI; Scott, M | 1 |
| Baldelli, S; Cellerino, R; Menichetti, ET; Miseria, S; Murer, B; Torresi, U; Tummarello, D | 1 |
| Chadwick, DJ; Gillatt, DA; Gingell, JC | 1 |
| Clarke, NW; George, NJ; McClure, J | 1 |
| Kuber, W; Spona, J; Viehberger, G; Zeillinger, R | 1 |
| Griffiths, K; Kaisary, AV; Peeling, WB; Tyrrell, CJ | 1 |
| Fischer, M; Flamm, J; Höltl, W; Pflüger, H; Tomschi, W | 1 |
| Campus, G; D'Atri, M; De Lisa, A; Migliari, R; Scarpa, RM; Serra, A; Usai, E; Zucca, I | 1 |
| Taylor, TK | 1 |
| Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Klippel, F; Lunglmayr, G; Tyrrell, CJ; Varenhorst, E | 1 |
| Lundmo, PI; Mjølnerød, OK; Samdal, F; Vada, K | 1 |
| Horlbeck, R; Jurincic, CD; Klippel, KF | 1 |
| Andrade, JA; Oliveira, MG; Oliveira, PD; Pina, F; Pina-Cabral, JM | 1 |
| Berná, L; Blanco, R; Carrió, I; Estorch, M; Germá, JR; Torres, G | 1 |
| Denis, L | 2 |
| Adenauer, H; de Voogt, HJ; Widdra, WG | 1 |
| Huhtaniemi, I; Parvinen, M; Rannikko, S; Venho, P | 1 |
| Korczak, D; Lindner, A; Siegel, YI | 1 |
| Falkson, CI; Falkson, G; Falkson, HC | 1 |
| Abel, P; Barton, C; Keane, P; Sandow, J; Waxman, J; Williams, G | 1 |
| Broglia, L; Francesca, F; Maffezzini, M; Rigatti, P; Villa, E | 1 |
| Clayton, RC; Gullick, W; Qayum, A; Sikora, K; Waxman, J | 1 |
| Braf, Z; Greenstein, A; Matzkin, H | 1 |
| Byerley, LO; Heber, D; Rajfer, J; Steiner, B; Swerdloff, RS; Tayek, JA | 1 |
| Kuhn, JM | 1 |
| Jerabek-Sandow, G; Sandow, J; Stoeckemann, K | 1 |
| Baak, JA; de Voogt, HJ; Kisman, OK | 1 |
| Ahmann, FR; Caplan, R; Gau, T; Kreis, W; Lesser, M; Scott, M; Vinciguerra, V | 1 |
| Blom, P; Johansen, TE; Kjellevold, K; Ogreid, P | 1 |
| Ayub, M; Levell, MJ | 1 |
| Ding, YQ; Huhtaniemi, I; Jaakkola, T; Kellokumpu-Lehtinen, P; Martikainen, H; Rönnberg, L; Tapanainen, J; Valavaara, R | 1 |
| Blackledge, GR; Boughton, BJ; Emtage, LA; George, J; Trethowan, C | 1 |
| Armitage, TG; Bono, A; Calais da Silva, F; Debruyne, F; Denis, L; Robinson, P; Smith, PH; Sylvester, R | 1 |
| Christensen, I; Denis, L; Iversen, P; Suciu, S; Sylvester, R | 2 |
| De Pauw, M; Denis, L; Newling, DW; Robinson, MR; Sylvester, R | 1 |
| Bond, A; Carvalho, AP; De Pauw, M; Denis, L; Keuppens, F; Newling, D; Ongena, P; Smith, P; Sylvester, R; Vermeylen, K | 1 |
| Christensen, MG; Friis, E; Hornbøl, P; Hvidt, V; Iversen, HG; Iversen, P; Klarskov, P; Krarup, T; Lund, F; Mogensen, P | 1 |
| Schulze, H; Senge, T | 1 |
| Bono, A; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Pinto de Carvalho, AP; Robinson, M; Smith, P; Sylvester, R | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F | 1 |
| Klarskov, P; Lund, F; Petersen, SE | 1 |
| Jacobi, GH | 1 |
| Hwang, YS; John, MJ; Krall, JM; McGowan, D; Perez, CA; Pilepich, MV | 1 |
| Girsch, E; Kratzik, C; Kuber, W; Spona, J; Treu, T; Zeillinger, R | 1 |
| Debruyne, FM; del Moral, PF; Delaere, KP; Dijkman, GA; Furr, BJ; Hutchinson, FJ; Kums, JJ; Plasman, JW | 1 |
| Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R | 1 |
| De Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, F; Studer, U; Sylvester, R | 1 |
| Di Silverio, F; Serio, M | 1 |
| Guidez, C | 1 |
| Debruyne, FM; Dijkman, GA; Fernandez del Moral, P; Furr, BJ; Hutchinson, FG; Plasman, JW; Pull, HC; van der Meijden, AP | 1 |
| Moffat, LE | 1 |
| Lunglmayr, G | 2 |
| Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, DW; Robinson, M; Smith, PH; Sylvester, R | 1 |
| Iversen, P | 1 |
| Cariou, G; Coloby, P; Colombel, P; Coulange, C; Fourcade, RO; Grise, P; Mangin, P; Poterre, M; Soret, JY | 1 |
| Boccardo, F; Cortellini, P; Decensi, A; Delli Ponti, U; Giuliani, L; Guarneri, D; Martorana, G; Oneto, F; Petracco, S; Rubagotti, A | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F; Serio, M | 1 |
| Qayum, A; Scaletsky, R; Waxman, J | 1 |
| Elder, JS; Gibbons, RP | 1 |
| de Voogt, HJ | 1 |
| Cooper, EH; Denis, L; Hetherington, JW; Newling, DW; Richards, B; Robinson, MR; Siddall, JK | 1 |
| Ikemoto, I; Machida, T | 1 |
| Blackledge, GR; Emtage, LA; Lewis, PW | 1 |
| Asano, M; Fujita, K; Isurugi, K; Kawabe, K; Kinoshita, K; Nakauchi, K; Niijima, T; Nishimura, Y; Nitoh, H; Yokoyama, M | 1 |
| Ayalon, D; Braf, Z; Lewyshon, O; Matzkin, H | 1 |
| Braf, Z; Greenstein, A; Kaver, I; Matzkin, H | 1 |
| Blom, JH; de Jong, FH; Hirdes, WH; Krauss, B; Kwekkeboom, DJ; Sandow, J; Schröder, FH; van't Veen, AJ | 1 |
| Abel, P; Cox, J; Farah, N; Fleming, J; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, JH; Williams, G | 1 |
| Heyman, J; Leiter, E | 1 |
| Billebaud, T; Costa, P; Dahan, R; Fiet, J; Grise, P; Husson, JM; Kuhn, JM; Louis, JF; Moulonguet, A; Navratil, H | 1 |
| Roila, F | 1 |
| James, N; Sandow, J; Thomas, H; Waxman, J; Williams, G | 1 |
| Hirasawa, K; Honma, Y; Isurugi, K; Kondo, Y; Oyamatsu, T | 1 |
| Dal Bo, V; Della Valentina, M; Francini, M; Lo Re, G; Magri, MD; Merlo, A; Monfardini, S; Talamini, R; Veronesi, A | 1 |
| Chodak, GW | 1 |
| Peeling, WB | 2 |
| Cassileth, BR; Hait, HI; Kennealey, GT; Schellhammer, PS; Seidmon, EJ; Soloway, MS; Vogelzang, NJ | 1 |
| Steg, A | 1 |
| Bono, A; Carvalho, AP; de Moura, JL; De Pauw, M; Denis, L; Newling, D; Ongena, P; Smith, P; Sylvester, R | 1 |
| Arkell, D; Blacklock, R; Emtage, LA; Hay, A; Hughes, M; Jones, M; Kelly, K; Rouse, A; Trethowan, C; Wallace, DM | 1 |
| Irie, S; Matsumura, Y; Nagai, A; Nanba, K; Ohashi, T; Ohashi, Y; Ohmori, H; Tanahashi, T; Yamashita, Y | 1 |
| Hansen, JB; Hansen, RI; Hvidt, V; Iversen, HG; Iversen, P; Mogensen, P; Pedersen, T; Rose, C; Stage, JG | 1 |
| Cordeschi, G; Francavilla, S; Galassi, P; Miano, L; Paradiso Galatioto, G; Properzi, G; Vicentini, C | 1 |
| Griffiths, K; Turkes, AO | 1 |
| Ceda, GP; Ceresini, G; Cortellini, P; Denti, L; Hoffman, AR; Valenti, G | 1 |
| Debruyne, F | 1 |
| Furr, BJ | 1 |
| Huhtaniemi, I; Nikula, H; Parvinen, M; Rannikko, S | 1 |
| de Jong, FH; Lamberts, SW; Uitterlinden, P | 1 |
| Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G | 1 |
| Argüelles, AE; Lascano, A; Poggi, U; Volmer, MC | 1 |
| de Jong, FH; de Voogt, HJ; Klign, JG; Schröder, FH | 1 |
| Chadha, DR; de Jong, FH; Lock, MT; Schröder, FH | 1 |
| Caselli, P; Crinò, L; Pasquarella, G; Roila, F | 1 |
| Faure, N; Lemay, A | 1 |
| Besser, GM; Hendry, WF; Man, A; Oliver, RT; Paris, AM; Tiptaft, RC; Waxman, J; Whitfield, HN | 1 |
| Eisenberger, MA; Friedman, MA; O'Dwyer, PJ | 1 |
| Hjertberg, H; Malmqvist, E; Svensson, M; Varenhorst, E | 1 |
| Bolton, C; Gingell, JC; Hartog, M; Kadow, C; Paisey, RB | 1 |
| Andrianne, R; Bouffioux, C; de Leval, J; Désirotte, J; Doupagne, M; Focan, C; Franchimont, P | 1 |
| Arkell, DG; Bailey, LC; Blackledge, G; Clayton, RN; Cottam, J; Farrar, D; Holder, G; Lynch, SS; Perren, TJ; Young, CH | 1 |
| Bouffioux, C; de Leval, J; Denis, L; Mahler, C | 2 |
| Ahmed, SR; Blacklock, NJ; Costello, CB; Grant, JB; Howell, A; Shalet, SM; Weatherson, T | 1 |
| Ahmed, SR; Blacklock, NJ; Costello, CB; Grant, JB; Howell, A; Shalet, SM | 1 |
| Opsomer, RJ; Van Cangh, PJ | 1 |
| Chin, JL; deHaan, HA; Greco, JM; Huben, RP; Murphy, GP; Scott, M | 1 |
| Boccon-Gibod, L; Dugue, MA; Laudat, MH; Steg, A | 1 |
| Calle Fernández, JR; Rubio Herrera, MA | 1 |
| Aso, Y; Ishigami, J; Itatani, H; Kotake, T; Matsuda, M; Ohi, Y; Ohkawa, T; Okajima, E; Osafune, M; Usami, M | 1 |
| Chadha, DR; de Jong, FH; de Voogt, HJ; Debruyne, FM; Karthaus, HF; Klijn, JG; Lock, TM; Matroos, AW; Schroeder, FH | 1 |
| Kotake, T; Matsuda, M; Okajima, E; Osafune, M; Sonoda, T; Usami, M | 1 |
| Ahmann, FR; Citrin, DL; deHaan, HA; Guinan, P; Jordan, VC; Kreis, W; Scott, M; Trump, DL | 1 |
| Beacock, CJ; Buck, AC; Griffiths, K; Peeling, WB; Rees, RW; Turkes, A; Walker, K; Zwinck, R | 1 |
| Ehrenthal, W; Happ, J; Jacobi, GH; Spindler, HW; von Wallenberg, H; Wenderoth, UK | 1 |
| Debruyne, FM; Denis, L; Keuppens, F; Lunglmayr, G; Mahler, C; Newling, D; Richards, B; Robinson, MR; Smith, PH; Weil, EH | 1 |
| Alcini, E; D'Addessi, A; Vacilotto, D | 1 |
| Claes, HI; Vandenbussche, L; Vereecken, RL | 1 |
| Albano, D; Bianco, A; Bolgan, A; Bono, AV; Frugoni, A; Morelli, A; Pozzi, E; Usai, E | 1 |
| Newling, DW | 1 |
| Greco, J; Huben, R; Murphy, GP | 1 |
| Matsumoto, K; Nakamura, M; Namiki, M; Nishimune, Y; Nonomura, N; Okuyama, A; Sonoda, T | 1 |
| Hjertberg, H; Kågedal, B; Nordenskjöld, B; Svensson, M; Varenhorst, E | 2 |
| de Voogt, HJ; Geldof, AA; Rao, BR | 1 |
| Griffiths, K; Peeling, WB; Turkes, AO | 1 |
| Arnold, AJ; Desmond, AD | 1 |
| Arkell, DG; Blackledge, GR; Cottam, J; Emtage, LA; Farrar, D; Hughes, MA; Perren, TJ; Stuart, NS; Wallace, DM; Young, CH | 1 |
| Garnick, MB; Seely, JH; Swanson, LJ | 1 |
| Hammar, M; Hjertberg, H; Mathson, K; Petersson, F; Varenhorst, E | 1 |
| Aaronson, N; Da Silva, FC | 1 |
| Debruyne, FM; Fernandez del Moral, P; Geboers, AD | 1 |
| Griffiths, K; Kaisary, AV; Peeling, WB; Ryan, PG; Turkes, A | 1 |
| Boulton, J; Croxson, MS; Harvey, V; Holdaway, IM; Ibbertson, HK; Knox, BS; List, A; Rutland, M | 1 |
| Akaza, H; Araki, T; Aso, Y; Isurugi, K; Kotake, T; Matsuda, M; Niijima, T; Okajima, E; Osafune, M; Usami, M | 1 |
| al-Abadi, H; Borgmann, V; Nagel, R | 1 |
| Debruyne, FM | 1 |
| Ehrenthal, W; Hohenfellner, R; Jacobi, GH; Spindler, HW; von Wallenberg, H; Wenderoth, UK | 1 |
| Debruyne, FM; Fernandez del Moral, P; Litjens, TT; Weil, EH | 1 |
| Debruyne, FM; Denis, L; Lunglmayer, G; Mahler, C; Newling, DW; Richards, B; Robinson, MR; Smith, PH; Weil, EH; Whelan, P | 1 |
| Bieglmayer, C; Girsch, E; Lunglmayr, G; Meixner, EM; Viehberger, G | 1 |
| Cirulli, C; Drago, JR; Nesbitt, JA | 1 |
| Javadpour, N | 1 |
| Kontturi, M; Lukkarinen, O | 1 |
| Kaldenhoff, H; Schulze, H; Senge, T | 1 |
| Ahmann, FR; de Haan, H; Jordan, VC; Kreis, W; Scott, M | 1 |
| Bouffioux, C | 1 |
| Budman, DR; Delli Bovi, P; Kreis, W; Vinciguerra, V | 1 |
| Akaza, H; Araki, T; Aso, Y; Itatani, H; Kotake, T; Matsuda, M; Nihsijima, T; Okajima, E; Osafune, M; Usami, M | 1 |
| Akaza, H; Isurugi, K; Kotake, T; Matsuda, M; Okajima, E; Osafune, M; Saitoh, Y; Sonoda, T; Usami, M | 1 |
| Adenis, L; Audhuy, B; Bugat, R; Colombel, P; Couette, JE; Grise, P; Khater, R; LePorz, B; Metz, R; Namer, M | 1 |
| Beacock, CJ | 1 |
| Bonichon, F; Coste, P; Lamarche, P; Mage, P; Mauriac, L; Richaud, P | 1 |
| Alcini, E; D'Addessi, A; Destito, A; Grasso, G | 1 |
| Boulton, J; Croxson, MS; Harvey, V; Holdaway, IM; Ibbertson, HK; Knox, BS | 1 |
| Denis, L; Mahler, C | 1 |
| Peeling, WB; Ryan, PG | 1 |
| Blackledge, GR; Emtage, LA; Hilton, C; Kelly, K; Trethowan, C | 1 |
| Akaza, H; Araki, T; Aso, Y; Itatani, H; Kotake, T; Matsuda, M; Niijima, T; Okajima, E; Osafune, M; Usami, M | 1 |
| Huhtaniemi, I; Nikula, H; Rannikko, S | 1 |
| Beier, B; Sandow, J | 1 |
| Alioth, H; Müller, J; Senn, E | 1 |
| Fiet, J; Moguilewsky, M; Raynaud, JP; Tournemine, C | 1 |
| Clayton, R; Huhtaniemi, I; Nikula, H; Rannikko, S | 1 |
| Ackman, CF; Faure, N; Koutsilieris, M; Laroche, B; Robert, G; Tolis, G | 1 |
| Debruyne, FM; Fernandez del Moral, P; Litjens, TT; van Laarhoven, JP; Weil, EH | 1 |
| Crum, A; Handelsman, DJ; Peterson, M; Rajfer, J; Steiner, B; Swerdloff, RS | 1 |
| Hickey, D; Soloway, MS; Todd, B | 1 |
| Akimoto, S; Fuse, H; Igarashi, T; Murakami, S; Shimazaki, J; Zama, S | 1 |
| Barnett, MJ; Besser, GM; Hendry, WF; Magill, PJ; Man, A; Oliver, RT; Sandow, J; Waxman, JH | 1 |
| Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y; Monfette, G | 1 |
| Bélanger, A; Brun, D; Dupont, A; Gagné, C; Giguère, M; Labrie, F; Lupien, PJ; Moorjani, S | 1 |
| Inaba, T; Kojima, M; Miyashita, H; Ohe, H; Watanabe, H | 1 |
| Ackman, CF; Koutsilieris, M | 1 |
| Dahlerup, J | 1 |
| Kennedy, PS; Klioze, SS; Mendez, RG; Naessig, VL; Presant, CA; Presant, SN; Soloway, MS; Todd, B; Wyres, MR; Yakabow, A | 1 |
| Baird, DT; Fraser, HM | 1 |
| Langkopf, B | 1 |
| Falkson, G; Vorobiof, DA | 1 |
| Bellina, M; Colombo, M; Fasolis, G; Fontana, D; Giusti, M; Isaia, GC; Randone, DF; Rolle, L | 1 |
| Cotard, M; Moguilewsky, M; Proulx, L; Raynaud, JP; Tournemine, C | 1 |
| Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Tewari, HD; Venner, PM | 1 |
| Navratil, H | 1 |
| Besser, GM; Hendry, BF; Lowe, D; Waxman, J; Whitfield, HN | 1 |
| Watanabe, H | 1 |
| Lynch, JH; O'Brien, WM | 1 |
| Dahl, KD; Hsueh, AJ; Huhtaniemi, IT; Rannikko, S | 1 |
| Hubert, J; Lamy, P; Seigneur, J; Trechot, PF | 1 |
| Ayalon, D; Braf, Z; Kaver, I; Lewyshon, O; Matzkin, H | 1 |
| Huben, RP; Murphy, GP | 1 |
| Isurugi, K; Kishimoto, T; Niijima, T; Shimazaki, J; Yoshida, O | 1 |
| Golomb, J; Korczak, D; Lindner, A; Siegel, Y | 1 |
| Klioze, SS; Miller, MF; Spiro, TP | 1 |
| Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Trachtenberg, J; Venner, PM | 1 |
| Ahmed, SR; Blacklock, NJ; Chowdhury, SD; Grant, J; Howell, A; Shalet, SM; Weatherson, T | 1 |
| Arkell, D; Bailey, LC; Blackledge, GR; Clayton, RN; Cottam, J; Perren, TJ | 1 |
| Denis, L; Lunglmayr, G; Mahler, C; Robinson, MR; Stitch, R; Walker, K | 1 |
| Nicholson, RI; Walker, KJ | 1 |
| Furr, BJ; Hutchinson, FG | 1 |
| Bloom, SR; Kerle, DJ; Roe, SM; Williams, G; Yeo, T | 1 |
| Griffiths, K; Harper, ME; Peeling, WB; Pierrepoint, CG; Turkes, AO; Walker, KJ; Wilson, DW | 1 |
| Paulson, DF | 1 |
| Hollander, V | 1 |
| Belanger, A; Dupont, A; Giguere, M; Labrie, F; Lachance, R | 1 |
| de Jong, FH; de Voogt, HJ; Debruyne, FM; Karthaus, HF; Klijn, JG; Schröder, FH | 1 |
| Hendry, WF; Oliver, RT; Waxman, JH; Whitfield, HN | 1 |
| Ford, KS; Kennedy, PS; Klioze, SS; Kosola, JW; Mendez, RG; Naessig, VL; Presant, CA; Soloway, MS; Wyres, MR; Yakabow, AL | 1 |
| Burk, K; Gropp, C | 1 |
| Pepperell, RJ | 1 |
17 review(s) available for buserelin and Prostatic Neoplasms
| Article | Year |
|---|---|
Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
Topics: Aged; Antineoplastic Agents, Hormonal; Buserelin; Cost-Benefit Analysis; Decision Trees; Drug Costs; Gonadotropin-Releasing Hormone; Goserelin; Humans; Italy; Leuprolide; Male; Models, Econometric; Proportional Hazards Models; Prostatic Neoplasms; Survival Analysis; Triptorelin Pamoate | 2011 |
Clinical applications of LHRH and its analogues.
Topics: Adolescent; Adult; Animals; Buserelin; Climacteric; Contraception; Corpus Luteum; Cryptorchidism; Female; Gonadotropin-Releasing Hormone; Humans; Hypogonadism; Luteinizing Hormone; Male; Ovulation; Pituitary Gland; Prostatic Neoplasms; Puberty, Delayed; Puberty, Precocious; Rats; Testis | 1983 |
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Topics: Acid Phosphatase; Androgen Antagonists; Buserelin; Drug Synergism; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms | 1983 |
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
Topics: Antineoplastic Agents, Hormonal; Buserelin; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Prostatic Neoplasms; Testosterone | 2000 |
Recent developments in endocrine treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1992 |
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
Topics: Animals; Breast Neoplasms; Buserelin; Drug Evaluation; Endometriosis; Female; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Gonadotropins; Goserelin; Humans; Leiomyoma; Male; Menstruation Disturbances; Polycystic Ovary Syndrome; Prostatic Neoplasms; Uterine Neoplasms | 1991 |
Endocrine therapy for advanced stage D prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Buserelin; Delayed-Action Preparations; Estradiol Congeners; Goserelin; Humans; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms | 1991 |
The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents.
Topics: Buserelin; Humans; Male; Meta-Analysis as Topic; Prostatic Neoplasms; Survival Rate | 1991 |
Buserelin in the treatment of prostatic cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Humans; Male; Pilot Projects; Prostatic Neoplasms | 1989 |
Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Topics: Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Prostatic Neoplasms | 1989 |
Endocrine treatment of prostate cancer.
Topics: Androgen Antagonists; Buserelin; Clinical Trials as Topic; Diethylstilbestrol; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms | 1989 |
Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.
Topics: Buserelin; Clinical Trials as Topic; Diethylstilbestrol; Gonadotropin-Releasing Hormone; Gonadotropins, Pituitary; Goserelin; Humans; Leuprolide; Male; Nafarelin; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Testosterone | 1986 |
Gonadotropin-releasing hormone analogs and prostatic cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Prostatic Neoplasms; Triptorelin Pamoate | 1988 |
[LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
Topics: Androgen Antagonists; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Dogs; Drug Therapy, Combination; Flutamide; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Cell Surface; Receptors, LHRH | 1985 |
Clinical applications of LHRH analogues.
Topics: Administration, Intranasal; Breast Neoplasms; Buserelin; Delayed-Action Preparations; Drug Therapy, Combination; Endometriosis; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Hirsutism; Humans; Leiomyoma; Male; Ovulation; Ovulation Induction; Premenstrual Syndrome; Prostatic Neoplasms; Puberty, Precocious; Uterine Neoplasms; Uterus | 1987 |
What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
Topics: Androgen Antagonists; Animals; Buserelin; Combined Modality Therapy; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Steroid | 1987 |
Endocrine factors in the treatment of prostatic cancer.
Topics: Buserelin; Castration; Chorionic Gonadotropin; Cosyntropin; Dexamethasone; Diethylstilbestrol; Estrogens; Goserelin; Hormones; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1985 |
99 trial(s) available for buserelin and Prostatic Neoplasms
| Article | Year |
|---|---|
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Topics: Aged; Androgen Antagonists; Buserelin; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Salvage Therapy; Survival Rate; Time Factors | 2009 |
[Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
Topics: Aged; Algorithms; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Chemotherapy, Adjuvant; Delayed-Action Preparations; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Octreotide; Prostatic Neoplasms; Somatostatin; Treatment Outcome | 2009 |
Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Buserelin; Drug Resistance, Neoplasm; Hot Flashes; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Reference Values; Testosterone | 2006 |
Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Buserelin; Carcinoma; Combined Modality Therapy; Drug Administration Routes; Drug Implants; Erectile Dysfunction; Follow-Up Studies; Gonadotropin-Releasing Hormone; Hot Flashes; Humans; Libido; Male; Middle Aged; Neoadjuvant Therapy; Prostate; Prostatic Neoplasms; Sexual Behavior; Testosterone; Time Factors | 2006 |
Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
Topics: Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Goserelin; Humans; Luteinizing Hormone; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Testosterone | 1984 |
Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
Topics: Administration, Intranasal; Aged; Buserelin; Clinical Trials as Topic; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Testosterone | 1983 |
Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH.
Topics: Acid Phosphatase; Adenocarcinoma; Alkaline Phosphatase; Bone and Bones; Buserelin; Hormones; Humans; Male; Neoplasm Staging; Orchiectomy; Prostate; Prostatic Neoplasms; Radiography; Receptors, Androgen; Ultrasonography | 1984 |
Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone Acetate; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1993 |
Combination treatment in M1 prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1993 |
Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Buserelin; Double-Blind Method; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prostatic Neoplasms | 1993 |
Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
Topics: Adenocarcinoma; Aged; Buserelin; Cardiovascular Diseases; Estradiol; Estradiol Congeners; Finland; Humans; Male; Prospective Studies; Prostatic Neoplasms | 1993 |
The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group".
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Buserelin; Estrogens; Humans; Male; Neoplasm Staging; Orchiectomy; Palliative Care; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Testosterone | 1996 |
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Combined Modality Therapy; Cyproterone Acetate; Disease-Free Survival; Flutamide; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Survival Rate | 1998 |
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis o
Topics: Acid Phosphatase; Administration, Intranasal; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Cause of Death; Cyproterone Acetate; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Subcutaneous; Male; Middle Aged; Orchiectomy; Pain Measurement; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1998 |
Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Buserelin; Diethylstilbestrol; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Time Factors; Treatment Outcome | 1992 |
Buserelin treatment of advanced prostatic carcinoma: prognostic factor analysis.
Topics: Age Factors; Aged; Buserelin; Humans; Male; Multivariate Analysis; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Remission Induction; Survival Analysis | 1992 |
Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aged, 80 and over; Buserelin; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Testosterone | 1991 |
Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group.
Topics: Alkaline Phosphatase; Buserelin; Follow-Up Studies; Goserelin; Humans; Male; Multivariate Analysis; Orchiectomy; Pain; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Testosterone | 1991 |
Total androgen ablation: European experience. The EORTC GU Group.
Topics: Aged; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1991 |
A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
Topics: Aged; Antineoplastic Agents; Buserelin; Diethylstilbestrol; Drug Implants; Follow-Up Studies; Goserelin; Humans; Male; Prostatic Neoplasms | 1991 |
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Buserelin; Goserelin; Humans; Ireland; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate; Testosterone; United Kingdom | 1991 |
Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate.
Topics: Aged; Buserelin; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Pilot Projects; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Time Factors | 1991 |
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Delayed-Action Preparations; Drug Tolerance; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Remission Induction; Time Factors; United Kingdom | 1991 |
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Remission Induction; Survival Rate | 1991 |
Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/month.
Topics: Aged; Aged, 80 and over; Antithrombin III; Buserelin; Diethylstilbestrol; Goserelin; Hemostasis; Humans; Male; Middle Aged; Prostatic Neoplasms | 1990 |
Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prognosis; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Complete androgen blockade: data from an EORTC 30853 trial.
Topics: Aged; Anilides; Buserelin; Combined Modality Therapy; Europe; Flutamide; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Topics: Aged; Androgen Antagonists; Anilides; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1990 |
Secondary treatment of advanced cancer of the prostate with Zoladex.
Topics: Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Goserelin; Humans; Lymphatic Metastasis; Male; Middle Aged; Prostatic Neoplasms; Remission Induction | 1990 |
Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy.
Topics: Buserelin; Diarrhea; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy | 1990 |
Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Drug Combinations; Drug Evaluation; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Risk Factors | 1990 |
Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyproterone Acetate; Europe; Humans; Male; Middle Aged; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Risk Factors | 1990 |
[Zoladex in prostatic carcinoma].
Topics: Aged; Antineoplastic Agents; Buserelin; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Male; Prostatic Neoplasms | 1990 |
[How can a nursing team participate in a clinical trial? Zoladex, flutamide trial].
Topics: Buserelin; Clinical Trials as Topic; Flutamide; Goserelin; Humans; Job Description; Male; Nursing Staff, Hospital; Prostatic Neoplasms | 1990 |
A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
Topics: Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Drug Evaluation; Goserelin; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1990 |
Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
Topics: Androgen Antagonists; Breast; Buserelin; Cardiovascular Diseases; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Goserelin; Humans; Male; Prospective Studies; Prostatic Neoplasms | 1990 |
A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Topics: Buserelin; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1990 |
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Topics: Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Carcinoma; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Liver Function Tests; Male; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1990 |
Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cyproterone; Cyproterone Acetate; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Prostatic Neoplasms; Testosterone | 1990 |
[Prostate cancer; hormonal treatment in a new stage?].
Topics: Aged; Buserelin; Clinical Trials as Topic; Erectile Dysfunction; Flushing; Humans; Male; Middle Aged; Palliative Care; Prostatic Neoplasms | 1986 |
The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
Topics: Acid Phosphatase; Alkaline Phosphatase; Antigens, Neoplasm; Biomarkers, Tumor; Bone Neoplasms; Buserelin; Diethylstilbestrol; Goserelin; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Random Allocation | 1987 |
Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer.
Topics: Adult; Aged; Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation; Testosterone | 1989 |
Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Evaluation; Humans; Imidazoles; Imidazolidines; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1989 |
Buserelin in the treatment of prostatic cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Humans; Male; Pilot Projects; Prostatic Neoplasms | 1989 |
Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Topics: Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Prostatic Neoplasms | 1989 |
Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Topics: Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Diethylstilbestrol; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Random Allocation; United Kingdom | 1989 |
Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
Topics: Anilides; Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Random Allocation | 1989 |
'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
Topics: Aged; Anilides; Buserelin; Clinical Trials as Topic; Drug Therapy, Combination; Flutamide; Goserelin; Humans; International Cooperation; Male; Multicenter Studies as Topic; Prognosis; Prostatic Neoplasms; Random Allocation | 1989 |
A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
Topics: Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Random Allocation; United Kingdom | 1989 |
A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.
Topics: Aged; Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Diethylstilbestrol; Goserelin; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Random Allocation; United Kingdom | 1989 |
Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1989 |
LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Buserelin; Carcinoma; Combined Modality Therapy; Delayed-Action Preparations; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms | 1989 |
Endocrine treatment of prostate cancer.
Topics: Androgen Antagonists; Buserelin; Clinical Trials as Topic; Diethylstilbestrol; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms | 1989 |
The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Phosphoric Monoester Hydrolases; Prostatic Neoplasms; Random Allocation; Testosterone | 1988 |
Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.
Topics: Aged; Buserelin; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Triptorelin Pamoate | 1985 |
Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.
Topics: Buserelin; Clinical Trials as Topic; Diethylstilbestrol; Gonadotropin-Releasing Hormone; Gonadotropins, Pituitary; Goserelin; Humans; Leuprolide; Male; Nafarelin; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Testosterone | 1986 |
[Treatment of cancer of the prostate with Zoladex Depot].
Topics: Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Goserelin; Humans; Male; Prostatic Neoplasms | 1986 |
Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
Topics: Buserelin; Delayed-Action Preparations; Goserelin; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Prostatic Neoplasms; Radioimmunoassay; Testosterone; Time Factors | 1986 |
Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Goserelin; Humans; Injections, Subcutaneous; Male; Prostatic Neoplasms; Random Allocation; Time Factors | 1987 |
[Treatment of prostatic carcinoma with daily subcutaneous injection of the LH-RH analogue, ICI 118630].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Buserelin; Drug Evaluation; Gonadotropins, Pituitary; Goserelin; Humans; Injections, Subcutaneous; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1986 |
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Drug Evaluation; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Statistics as Topic; Testosterone | 1987 |
Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group.
Topics: Buserelin; Clinical Trials as Topic; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Random Allocation; Testosterone | 1987 |
Gonadotropin-releasing hormone analogs and prostatic cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Prostatic Neoplasms; Triptorelin Pamoate | 1988 |
Quality of life assessment in prostatic cancer.
Topics: Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires | 1988 |
LHRH-analogues therapy for metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Buserelin; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Goserelin; Humans; Male; Middle Aged; Netherlands; Prostatic Neoplasms; Testosterone | 1988 |
A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma--a multi-centre clinical study.
Topics: Aged; Aged, 80 and over; Buserelin; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Random Allocation | 1988 |
[Endocrine therapy of prostatic carcinoma with slow release (depot) formulation of the LH-RH analog ICI 118630 (Zoladex)].
Topics: Buserelin; Delayed-Action Preparations; Drug Evaluation; Goserelin; Humans; Male; Prostatic Neoplasms | 1988 |
Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
Topics: Aged; Aged, 80 and over; Biopsy, Needle; Buserelin; Carcinoma; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Cytophotometry; DNA, Neoplasm; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Staging; Prostate; Prostatic Neoplasms; Remission Induction | 1988 |
Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Topics: Aged; Buserelin; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Humans; Lymphatic Metastasis; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Netherlands; Orchiectomy; Prostatic Neoplasms; Remission Induction; Time Factors | 1988 |
Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
Topics: Adenocarcinoma; Administration, Intranasal; Antineoplastic Agents; Biomarkers, Tumor; Buserelin; Clinical Trials as Topic; Gonadotropin-Releasing Hormone; Humans; Injections, Intramuscular; Lymphatic Metastasis; Male; Neoplasm Staging; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate | 1988 |
Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate.
Topics: Aged; Aged, 80 and over; Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Goserelin; Hormones; Humans; Male; Middle Aged; Prostatic Neoplasms; Spermatogenesis; Time Factors | 1988 |
Selected advances in therapy of urologic cancer--luteinizing hormone releasing hormone (LHRH) and biologic response modifier (BUR).
Topics: Adenocarcinoma; Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Goserelin; Humans; Injections, Subcutaneous; Interleukin-2; Male; Orchiectomy; Prostatic Neoplasms; Random Allocation; Recombinant Proteins | 1988 |
Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
Topics: Androgen Antagonists; Androgens; Buserelin; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Random Allocation | 1988 |
Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
Topics: Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Time Factors | 1988 |
[Clinical efficacy of long-term treatment with LH-RH analogue, ICI 118630 (Zoladex), in prostatic cancer patients. The Zoladex Multicenter Study Group].
Topics: Buserelin; Drug Evaluation; Goserelin; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Remission Induction; Time Factors | 1988 |
LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Topics: Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Follicle Stimulating Hormone; Goserelin; Humans; Injections, Subcutaneous; Japan; Luteinizing Hormone; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Random Allocation; Remission Induction; Testosterone | 1988 |
Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Follicle Stimulating Hormone; France; Goserelin; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate; Prostatic Neoplasms | 1988 |
U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
Topics: Aged; Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Goserelin; Humans; Injections, Subcutaneous; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Remission Induction; Testosterone; United Kingdom | 1988 |
Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
Topics: Buserelin; Delayed-Action Preparations; Diethylstilbestrol; England; Follow-Up Studies; Goserelin; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Random Allocation; Remission Induction; Testosterone | 1988 |
[Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
Topics: Aged; Buserelin; Castration; Clinical Trials as Topic; Estrogens; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Neoplasms | 1988 |
Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Combined Modality Therapy; Diethylstilbestrol; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1986 |
Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
Topics: Androgen Antagonists; Buserelin; Clinical Trials as Topic; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms | 1987 |
Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1987 |
A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
Topics: Administration, Intranasal; Buserelin; Clinical Trials as Topic; Delayed-Action Preparations; Drug Implants; England; Follow-Up Studies; Humans; Male; Prohibitins; Prostatic Neoplasms; Testis | 1988 |
Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
Topics: Buserelin; Clinical Trials as Topic; Diethylstilbestrol; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Time Factors | 1988 |
A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Diethylstilbestrol; Humans; Male; Methotrexate; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms | 1988 |
[Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
Topics: Administration, Intranasal; Aged; Aged, 80 and over; Buserelin; Drug Evaluation; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prognosis; Prostatic Neoplasms; Testosterone | 1988 |
A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients.
Topics: Administration, Intranasal; Administration, Oral; Buserelin; Diethylstilbestrol; Humans; Injections, Subcutaneous; Male; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostatic Neoplasms; Random Allocation; Testosterone | 1988 |
Total androgen blockade for metastatic cancer of the prostate.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Placebos; Prognosis; Prostatic Neoplasms; Random Allocation; Remission Induction | 1988 |
An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Topics: Buserelin; Carcinoma; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Goserelin; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone; Time Factors | 1985 |
Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome.
Topics: Acid Phosphatase; Bone and Bones; Buserelin; Estradiol; Flushing; Follow-Up Studies; Humans; Male; Orchiectomy; Prostatic Neoplasms; Radionuclide Imaging; Testosterone; Ultrasonics | 1985 |
Will gonadotrophin releasing hormone analogues profoundly affect gynaecological practice?
Topics: Amenorrhea; Buserelin; Clinical Trials as Topic; Endometriosis; Female; Gonadotropin-Releasing Hormone; Humans; Male; Ovulation; Prostatic Neoplasms; Uterine Neoplasms | 1985 |
198 other study(ies) available for buserelin and Prostatic Neoplasms
| Article | Year |
|---|---|
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries.
Topics: Androgen Antagonists; Buserelin; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Prostatic Neoplasms; Triptorelin Pamoate; United States; United States Food and Drug Administration | 2023 |
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Buserelin; Diarrhea; Flutamide; Gastrectomy; Glaucoma; Gonadotropin-Releasing Hormone; Hernia, Hiatal; Humans; Luteinizing Hormone; Male; Nitriles; Peptic Ulcer; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2009 |
Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Topics: Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Prescriptions; Flutamide; Humans; Imidazolidines; Leuprolide; Male; Patient Education as Topic; Patient Satisfaction; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis | 2008 |
Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
Topics: Aged; Androgen Antagonists; Buserelin; Combined Modality Therapy; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Survival Rate | 2009 |
Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Body Mass Index; Buserelin; Drug Therapy, Combination; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunoassay; Retrospective Studies; Testosterone; Treatment Outcome | 2012 |
Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus.
Topics: Adenoviridae; Antineoplastic Agents, Hormonal; Buserelin; Cell Division; Genetic Therapy; Genetic Vectors; Humans; Male; Prostatic Neoplasms; Receptors, LHRH; Signal Transduction; Transduction, Genetic; Tumor Cells, Cultured | 2003 |
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Topics: Aged; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Buserelin; Clinical Trials, Phase II as Topic; Hemoglobins; Humans; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sickness Impact Profile; Testosterone | 2005 |
Recurrent auricular chondritis and cartilage repair.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Buserelin; Ear Cartilage; Ear Deformities, Acquired; Humans; Male; Polychondritis, Relapsing; Prostatic Neoplasms | 2005 |
Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery.
Topics: Aged; Antineoplastic Agents, Hormonal; Buserelin; Fatigue; Health Status; Hematocrit; Hemoglobins; Humans; Male; Prostatectomy; Prostatic Neoplasms; Quality of Life; Salvage Therapy; Testosterone | 2005 |
The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Buserelin; Drug Therapy; Humans; Interview, Psychological; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Quality of Life; Sexuality; Social Identification; Tosyl Compounds | 2005 |
Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Buserelin; Castration; Combined Modality Therapy; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1984 |
Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
Topics: Administration, Intranasal; Aged; Buserelin; Depression, Chemical; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1982 |
New treatment for prostatic cancer.
Topics: Buserelin; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms | 1983 |
New treatment for prostatic cancer.
Topics: Administration, Intranasal; Buserelin; Humans; Male; Prostatic Neoplasms | 1983 |
Acne conglobata responding to buserelin, a gonadotrophin-releasing hormone analogue.
Topics: Acne Vulgaris; Adenocarcinoma; Aged; Buserelin; Humans; Male; Prostatic Neoplasms | 1983 |
Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
Topics: Buserelin; Goserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1984 |
Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
Topics: Buserelin; Delayed-Action Preparations; Goserelin; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1984 |
The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
Topics: Adenocarcinoma; Buserelin; Castration; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1984 |
Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
Topics: Acid Phosphatase; Alkaline Phosphatase; Analgesia; Bone Neoplasms; Buserelin; Goserelin; Hormones; Humans; Male; Prostatic Neoplasms | 1984 |
Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension.
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Animals; Buserelin; Castration; Dogs; Estrogens; Gonadotropin-Releasing Hormone; Humans; Leydig Cells; Luteinizing Hormone; Male; Prostatic Neoplasms; Receptors, Cell Surface; Receptors, LH; Receptors, LHRH | 1982 |
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Topics: Administration, Intranasal; Aged; Buserelin; Estradiol; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Prolactin; Prospective Studies; Prostatic Neoplasms; Testosterone | 1983 |
New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
Topics: Androgen Antagonists; Animals; Buserelin; Drug Therapy, Combination; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats; Testis | 1983 |
Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
Topics: Aged; Androgens; Buserelin; Dihydrotestosterone; Gonadotropin-Releasing Hormone; Hormones; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testis; Testosterone | 1983 |
New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
Topics: Androgen Antagonists; Animals; Buserelin; Castration; Dihydrotestosterone; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms; Rats; Seminal Vesicles; Testosterone | 1983 |
Treatment of prostatic cancer with LH-RH analogues.
Topics: Aged; Buserelin; DNA, Neoplasm; Hormones; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1983 |
Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma.
Topics: Acid Phosphatase; Alkaline Phosphatase; Buserelin; Hormones; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Radiography; Testosterone | 1983 |
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testosterone | 1983 |
Transabdominal ultrasonography in the evaluation of patients with advanced prostatic carcinoma: effects of castration and of chronic administration of a gonadotropin releasing hormone agonistic analogue.
Topics: Buserelin; Castration; Hormones; Humans; Male; Prostatic Neoplasms; Testosterone; Ultrasonography | 1983 |
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Bone and Bones; Buserelin; Castration; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testis; Testosterone | 1983 |
Analogues of gonadotrophin releasing hormone.
Topics: Animals; Breast Neoplasms; Buserelin; Child; Dogs; Female; Humans; Male; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Puberty, Precocious | 1984 |
[1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
Topics: Aged; Buserelin; DNA, Neoplasm; Follow-Up Studies; Histocytochemistry; Humans; Luteinizing Hormone; Male; Neoplasm Staging; Prostatic Neoplasms; Testosterone | 1983 |
LHRH-agonist treatment in metastatic prostate carcinoma.
Topics: Aged; Alkaline Phosphatase; Bone Neoplasms; Buserelin; Drug Evaluation; Humans; Male; Neoplasm Metastasis; Prostate; Prostatic Neoplasms; Testosterone; Time Factors | 1984 |
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
Topics: Acid Phosphatase; Adenocarcinoma; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Testosterone | 1984 |
Newer methods of hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Megestrol; Megestrol Acetate; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms | 1984 |
Metastatic prostate cancer: hormone dependency and therapeutic efficacy of GnRH analogues.
Topics: Buserelin; Castration; Combined Modality Therapy; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms | 1984 |
Failure of long term luteinising hormone releasing hormone to suppress testosterone.
Topics: Buserelin; Humans; Male; Prostatic Neoplasms; Testosterone | 1984 |
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
Topics: Buserelin; Carcinoma; Estradiol; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1982 |
Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
Topics: Administration, Intranasal; Aged; Buserelin; Dihydrotestosterone; Estradiol; Gonadotropin-Releasing Hormone; Humans; Hydroxyprogesterones; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone; Time Factors | 1982 |
Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.
Topics: Adenocarcinoma; Administration, Intranasal; Aged; Buserelin; Gonadotropin-Releasing Hormone; Hormones; Humans; Luteinizing Hormone; Male; Middle Aged; Monitoring, Physiologic; Prolactin; Prostatic Neoplasms; Testosterone | 1982 |
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Bone Neoplasms; Buserelin; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats | 1982 |
Kinetic analysis of prostatic volume in patients with stage D prostatic cancer treated with LHRH analogues in relation to prognosis.
Topics: Aged; Aged, 80 and over; Buserelin; Disease Progression; Follicle Stimulating Hormone; Humans; Kinetics; Leuprolide; Luteinizing Hormone; Male; Predictive Value of Tests; Prognosis; Prostate; Prostatic Neoplasms; Survival Analysis | 1995 |
Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
Topics: Animals; Buserelin; Cell Division; Drug Screening Assays, Antitumor; Gonadotropin-Releasing Hormone; Goserelin; Male; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Receptors, LHRH; Tumor Cells, Cultured | 1994 |
Serum metalloproteinases and their inhibitors: markers for malignant potential.
Topics: Arthritis, Rheumatoid; Biomarkers, Tumor; Buserelin; Collagenases; Enzyme-Linked Immunosorbent Assay; Glycoproteins; Humans; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Metalloendopeptidases; Neoplasm Metastasis; Predictive Value of Tests; Prostatic Neoplasms; Proteins; Reference Values; Reproducibility of Results; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases | 1994 |
Effect of LHRH analog on the seminal vesicles evaluated by transrectal sonography.
Topics: Aged; Aged, 80 and over; Buserelin; Follicle Stimulating Hormone; Humans; Leuprolide; Luteinizing Hormone; Male; Prostate; Prostatic Neoplasms; Seminal Vesicles; Testosterone | 1993 |
Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a].
Topics: Aged; Apolipoproteins B; Buserelin; Humans; Lipids; Lipoprotein(a); Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 1996 |
[Current aspects in the therapy of prostatic cancer].
Topics: Buserelin; Castration; Humans; Male; Prostatectomy; Prostatic Neoplasms; Survival Rate | 1996 |
Potentiating effect of buserelin acetate, an LHRH agonist, on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats.
Topics: Animals; Antineoplastic Agents, Hormonal; Buserelin; Cell Division; Cell Nucleus; Contraceptive Agents, Male; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cells; Epithelium; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Male; Orchiectomy; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Rats; Rats, Wistar; Testosterone | 1997 |
Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
Topics: Antineoplastic Agents; Binding Sites; Buserelin; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Methionine; Prostatic Neoplasms; Receptors, LHRH; Thymidine; Tumor Cells, Cultured | 1992 |
Value of biochemical markers in the management of disseminated prostatic cancer.
Topics: Acid Phosphatase; Alkaline Phosphatase; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Follow-Up Studies; Goserelin; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 1992 |
Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma.
Topics: Androgen Antagonists; Anilides; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 1992 |
Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Biopsy, Needle; Buserelin; DNA, Neoplasm; Estrogens; Follow-Up Studies; Goserelin; Humans; Male; Multivariate Analysis; Orchiectomy; Ploidies; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms | 1992 |
Re: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. A. V. Kaisary et al. Br. J. Urol., 67, 502-508, 1991.
Topics: Antineoplastic Agents; Buserelin; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1992 |
[A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
Topics: Aged; Androgen Antagonists; Angina Pectoris; Buserelin; Calcitonin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Hyperhidrosis; Male; Prostatic Neoplasms | 1992 |
Hormonal cytoreduction and radiotherapy for carcinoma of the prostate.
Topics: Buserelin; Combined Modality Therapy; Goserelin; Humans; Male; Prostatic Neoplasms | 1992 |
Pituitary hyperplasia after goserelin (LHRH-analogue) therapy.
Topics: Adrenocorticotropic Hormone; Aged; Buserelin; Goserelin; Growth Hormone; Humans; Hyperplasia; Immunohistochemistry; Male; Neoplasm Metastasis; Orchiectomy; Pituitary Gland, Anterior; Prostatic Neoplasms | 1991 |
Prolonged treatment with the GnRH analogue buserelin does not affect alpha-subunit production by the pituitary gonadotroph.
Topics: Buserelin; Cross Reactions; Follicle Stimulating Hormone; Glycoprotein Hormones, alpha Subunit; Humans; Immunoradiometric Assay; Luteinizing Hormone; Male; Prostatic Neoplasms; Radioimmunoassay; Testosterone; Time Factors | 1990 |
Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Brachytherapy; Buserelin; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms | 1990 |
Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Survival Rate | 1990 |
Goserelin--another LH-RH analog for prostate cancer.
Topics: Buserelin; Drug Implants; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Palliative Care; Prostatic Neoplasms | 1990 |
Dissociated effect of buserelin on luteinizing hormone (LH) and alpha subunit in men.
Topics: Aged; Buserelin; Chromatography, Gel; Follicle Stimulating Hormone; Glycoprotein Hormones, alpha Subunit; Humans; Immunoradiometric Assay; Luteinizing Hormone; Male; Middle Aged; Pituitary Gland; Prostatic Neoplasms; Radioimmunoassay; Testis; Testosterone | 1990 |
Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Topics: Aged; Antigens, Neoplasm; Buserelin; Combined Modality Therapy; Goserelin; Humans; Male; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 1991 |
Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Topics: Aged; Buserelin; Follicle Stimulating Hormone; Gonadotropins; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Prolactin; Prostatic Neoplasms; Testosterone | 1991 |
Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report.
Topics: Buserelin; Carcinoma; Flutamide; Goserelin; Humans; Lung Neoplasms; Lymphangitis; Male; Middle Aged; Prostatic Neoplasms | 1991 |
Medical or surgical orchidectomy: the patients' choice.
Topics: Aged; Buserelin; Choice Behavior; Consumer Behavior; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1991 |
Preferential preservation of bone mineralisation by LHRH agonists in the treatment of metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Buserelin; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1991 |
Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Buserelin; Goserelin; Humans; Male; Prostatic Neoplasms; Testis; Time Factors | 1991 |
Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Vision, Ocular | 1991 |
Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate?
Topics: Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Buserelin; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms | 1991 |
Proteins C and S in patients with advanced prostatic cancer.
Topics: Buserelin; Carrier Proteins; Complement C4b; Complement Inactivator Proteins; Flutamide; Glycoproteins; Humans; Male; Orchiectomy; Prostatic Neoplasms; Protein C; Protein S | 1991 |
Bone marrow regeneration after hormonal therapy in patients with bone metastases from prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Bone Marrow; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Organotechnetium Compounds; Prostatic Neoplasms; Radionuclide Imaging; Regeneration | 1991 |
Maximal androgen blockade in prostatic cancer.
Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms | 1991 |
Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Buserelin; Cyproterone; Cyproterone Acetate; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Radioimmunoassay; Receptors, Gonadotropin; Testis; Testosterone | 1991 |
Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Buserelin; Follow-Up Studies; Humans; Male; Prolactin; Prostatic Neoplasms; Time Factors | 1991 |
Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
Topics: Administration, Intranasal; Adult; Aged; Aged, 80 and over; Buserelin; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Luteinizing Hormone; Male; Middle Aged; Monitoring, Physiologic; Prostatic Neoplasms; Testosterone | 1991 |
Three-monthly GnRH agonist (buserelin) for prostatic cancer.
Topics: Buserelin; Delayed-Action Preparations; Drug Evaluation; Humans; Male; Prostatic Neoplasms; Testosterone | 1990 |
Long-term results with the Gn-RH analogue, buserelin, in metastatic prostate cancer.
Topics: Aged; Buserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1990 |
The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors.
Topics: Buserelin; Cell Division; Cell Line; Dose-Response Relationship, Drug; Humans; Male; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Radioimmunoassay | 1990 |
Clinical importance of prostatic measurements in follow-up of GnRH analogue-treated prostatic carcinoma patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Buserelin; Follow-Up Studies; Humans; Male; Middle Aged; Prostate; Prostatic Neoplasms; Remission Induction; Survival Rate; Ultrasonography; Urination | 1990 |
Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer.
Topics: Aged; Body Composition; Buserelin; Energy Metabolism; Gonadotropin-Releasing Hormone; Hormones; Humans; Leucine; Male; Nutritional Physiological Phenomena; Prostatic Neoplasms | 1990 |
[Hormonal treatments of prostate cancer].
Topics: Androgen Antagonists; Buserelin; Carcinoma; Diethylstilbestrol; Drug Therapy, Combination; Estrogens; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms | 1990 |
Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues.
Topics: Animals; Buserelin; Creatinine; Delayed-Action Preparations; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Infusion Pumps, Implantable; Macaca mulatta; Male; Prostatic Neoplasms; Testosterone | 1990 |
Reversibility of the effect of LHRH agonists and other antiandrogenic hormones on the testis: a histomorphometric study.
Topics: Adult; Aged; Aged, 80 and over; Buserelin; Humans; Leydig Cells; Male; Middle Aged; Prostatic Neoplasms; Spermatogenesis; Testis | 1990 |
Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin.
Topics: Age Factors; Aged; Alkaline Phosphatase; Analysis of Variance; Antineoplastic Agents; Buserelin; Goserelin; Health Status; Humans; Male; Multivariate Analysis; Neoplasm Staging; Pain; Predictive Value of Tests; Proportional Hazards Models; Prostatic Neoplasms; Remission Induction; Testosterone | 1990 |
Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.
Topics: Aged; Buserelin; Goserelin; Humans; Leydig Cells; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Spermatogenesis; Testis; Testosterone; Time Factors | 1990 |
Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androgens; Androstenedione; Anilides; Antineoplastic Agents; Buserelin; Dehydroepiandrosterone; Depression, Chemical; Flutamide; Goserelin; Humans; Hydroxyprogesterones; Male; Orchiectomy; Prostatic Neoplasms; Testosterone | 1990 |
The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
Topics: Adult; Aged; Biological Assay; Buserelin; Endometriosis; Female; Fluorescent Antibody Technique; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Menopause; Middle Aged; Nafarelin; Orchiectomy; Ovarian Neoplasms; Ovariectomy; Prostatic Neoplasms; Radioimmunoassay; Uterine Neoplasms | 1990 |
Zoladex said to be "as effective as surgery" for prostate cancer.
Topics: Buserelin; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1990 |
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1990 |
Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Luteinizing Hormone; Male; Premedication; Prostatic Neoplasms; Testosterone; Time Factors | 1990 |
LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade.
Topics: Antineoplastic Agents; Buserelin; Carcinoma; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1990 |
[Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Buserelin; Carcinoma; Drug Implants; Goserelin; Humans; Male; Middle Aged; Organ Size; Prospective Studies; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Testis; Testosterone | 1990 |
A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Buserelin; Drug Tolerance; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Pituitary Gland; Prostatic Neoplasms; Testosterone | 1990 |
Autocrine stimulation by gonadotrophin-releasing hormone-like factors of human hormone-responsive prostate cancer cells in culture.
Topics: Buserelin; Cell Division; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasms, Hormone-Dependent; Peptide Hydrolases; Prostatic Neoplasms; Radioimmunoassay; Receptors, LHRH; Tumor Cells, Cultured | 1990 |
Advances in the treatment of metastatic prostatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Diethylstilbestrol; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Neoplasm Metastasis; Orchiectomy; Palliative Care; Prostatic Neoplasms | 1985 |
Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex).
Topics: Acid Phosphatase; Aged; Aged, 80 and over; alpha-2-HS-Glycoprotein; Antigens; Blood Proteins; Buserelin; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Orosomucoid; Prolactin; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunoassay; Testosterone | 1986 |
[Hormone therapy of male genital cancer (prostatic cancer)].
Topics: Buserelin; Chlormadinone Acetate; Estramustine; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitrogen Mustard Compounds; Prostatic Neoplasms | 1987 |
[Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
Topics: Aged; Aged, 80 and over; Buserelin; Drug Evaluation; Follicle Stimulating Hormone; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Prognosis; Prolactin; Prostatic Hyperplasia; Prostatic Neoplasms; Testosterone; Thyrotropin | 1988 |
Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Follow-Up Studies; Hormones; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms | 1989 |
Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Carcinoma; Clinical Enzyme Tests; Drug Evaluation; Follow-Up Studies; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 1989 |
Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
Topics: Aged; Buserelin; Carcinoma; Delayed-Action Preparations; Drug Implants; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1989 |
Dramatic response of pulmonary metastasis from prostatic cancer to LH-RH agonist treatment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Buserelin; Gonadotropin-Releasing Hormone; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Rectal Diseases; Ulcer | 1989 |
A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer.
Topics: Buserelin; Delayed-Action Preparations; Drug Evaluation; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone; Time Factors | 1989 |
[Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Buserelin; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Testis; Testosterone | 1989 |
Buserelin treatment of advanced prostatic cancer: a phase II study.
Topics: Aged; Bone Neoplasms; Buserelin; Drug Evaluation; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Remission Induction | 1989 |
Patients' choice of treatment in stage D prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Attitude to Health; Buserelin; Consumer Behavior; Decision Making; Follow-Up Studies; Goserelin; Humans; Informed Consent; Male; Middle Aged; Orchiectomy; Patient Participation; Prostatic Neoplasms; Surveys and Questionnaires | 1989 |
[Treatment of cancer of the prostate. Role of gonadorelin analogs].
Topics: Buserelin; Castration; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Prostatic Neoplasms | 1989 |
[Clinical and endocrinological studies of the luteinizing hormone-releasing hormone analogue therapy in prostatic cancer patients].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Buserelin; Dihydrotestosterone; Drug Evaluation; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Remission Induction; Testosterone | 1989 |
Testicular changes after treatment with a GnRH analog (buserelin) in association with cyproterone acetate in men with prostatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Humans; Leydig Cells; Male; Middle Aged; Prostatic Neoplasms; Sertoli Cells; Spermatogenesis; Testicular Diseases; Testosterone | 1989 |
Androgens do not regulate the growth hormone response to GHRH in elderly men.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1989 |
Luteinising hormone-releasing hormone analogues alone in the treatment of advanced disease.
Topics: Buserelin; Goserelin; Humans; Male; Prostatic Neoplasms | 1989 |
LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
Topics: Androgen Antagonists; Buserelin; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1989 |
Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
Topics: Animals; Buserelin; Female; Goserelin; Male; Mammary Neoplasms, Experimental; Prostatic Neoplasms; Rats | 1989 |
Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer.
Topics: Aged; Buserelin; Chorionic Gonadotropin; Cyclic AMP; Drug Evaluation; Histocytochemistry; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Receptors, FSH; Receptors, LH; Testis; Testosterone; Time Factors | 1988 |
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Topics: Adrenocorticotropic Hormone; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Goserelin; Imidazoles; Imidazolidines; Ketoconazole; Luteinizing Hormone; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains | 1988 |
Lung metastases of prostate carcinoma cleared by intranasal GRH analogue.
Topics: Adenocarcinoma; Administration, Intranasal; Aged; Buserelin; Humans; Lung Neoplasms; Male; Prostatic Neoplasms | 1985 |
Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma.
Topics: Buserelin; Cyproterone; Drug Therapy, Combination; Humans; Male; Prostatic Neoplasms | 1985 |
Long-term effects of buserelin on plasma testosterone and luteinising hormone concentrations.
Topics: Buserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1985 |
Increased bone pain after suspension of buserelin treatment in disseminated prostatic cancer.
Topics: Bone Neoplasms; Buserelin; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms | 1988 |
Inhibition of testicular androgen biosynthesis by chronic administration of a potent LHRH agonist in adult men.
Topics: Administration, Intranasal; Adult; Androgens; Buserelin; Dose-Response Relationship, Drug; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Orchiectomy; Prostatic Neoplasms; Testis; Testosterone; Time Factors; Triptorelin Pamoate | 1985 |
Antithrombin III concentration, thrombosis, and treatment with luteinising hormone releasing hormone agonist in prostatic carcinoma.
Topics: Aged; Antithrombin III; Buserelin; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms | 1986 |
Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.
Topics: Buserelin; Cyproterone; Cyproterone Acetate; Goserelin; Humans; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Prostatic Neoplasms; Urologic Diseases | 1986 |
[Treatment of advanced cancer of the prostate using LHRH analogs. How can a possible initial flare-up be prevented?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Diethylstilbestrol; Goserelin; Humans; Male; Prostatic Neoplasms | 1986 |
A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
Topics: Aged; Aged, 80 and over; Buserelin; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone; Time Factors | 1986 |
Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Topics: Aged; Aged, 80 and over; Buserelin; Drug Administration Schedule; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Testosterone | 1986 |
Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
Topics: Aged; Buserelin; Carcinoma; Delayed-Action Preparations; Diethylstilbestrol; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1987 |
Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
Topics: Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Humans; Male; Premedication; Prostatic Neoplasms; Testosterone | 1986 |
[Treatment of carcinoma of the prostate with analogs of LHRH].
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Prostatic Neoplasms; Triptorelin Pamoate | 1986 |
Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
Topics: Buserelin; Cyproterone; Cyproterone Acetate; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Prospective Studies; Prostatic Neoplasms; Testosterone; Time Factors | 1987 |
[Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Topics: Aged; Buserelin; Delayed-Action Preparations; Drug Administration Schedule; Drug Evaluation; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1987 |
The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Bone Neoplasms; Buserelin; Delayed-Action Preparations; Goserelin; Humans; Luteinizing Hormone; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Random Allocation; Testosterone | 1987 |
Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
Topics: Administration, Intranasal; Antineoplastic Agents; Biomarkers, Tumor; Buserelin; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Humans; Injections, Intramuscular; Luteinizing Hormone; Male; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1987 |
Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
Topics: Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1987 |
LH-RH analogue treatment of advanced prostatic cancer.
Topics: Buserelin; Goserelin; Humans; Male; Prostatic Neoplasms | 1987 |
Treatment of advanced carcinoma of the prostate by LHRH-agonists.
Topics: Buserelin; Cyproterone; Cyproterone Acetate; Goserelin; Humans; Male; Prostatic Neoplasms; Testosterone | 1987 |
Preliminary report on a phase II multicentric study on depot LH-RH analogue in advanced prostatic cancer.
Topics: Buserelin; Drug Evaluation; Goserelin; Humans; Male; Prostatic Neoplasms | 1987 |
Treatment of advanced prostatic cancer with LHRH-analogues. Prevention of "flare-up" phenomenon.
Topics: Buserelin; Goserelin; Humans; Male; Prostatic Neoplasms; Testosterone | 1987 |
The value of reversible androgen suppression as a diagnostic test.
Topics: Androgen Antagonists; Buserelin; Estrogens; Goserelin; Humans; Male; Prostatic Neoplasms | 1987 |
Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
Topics: Buserelin; Delayed-Action Preparations; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Pituitary Gland; Prostatic Neoplasms; Testis; Testosterone; Time Factors | 1987 |
Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro.
Topics: Aged; Buserelin; Chorionic Gonadotropin; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Organ Culture Techniques; Prostatic Neoplasms; Receptors, FSH; Receptors, LH; Testis; Testosterone | 1987 |
[Treatment of prostatic cancer with monthly injections of an LH-RH analog].
Topics: Aged; Buserelin; Goserelin; Humans; Injections, Subcutaneous; Male; Middle Aged; Prostatic Neoplasms | 1987 |
Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
Topics: Androgens; Animals; Buserelin; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Goserelin; Kidney; Male; Neoplasms, Hormone-Dependent; Organ Size; Prostate; Prostatic Neoplasms; Rats; Seminal Vesicles; Testis; Testosterone | 1987 |
Gonadotrophin hormone releasing analogues open new doors in cancer treatment.
Topics: Aged; Aged, 80 and over; Buserelin; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1987 |
Phase II study of Zoladex depot in advanced prostatic cancer with special reference to criteria of response and survival.
Topics: Aged; Aged, 80 and over; Buserelin; Castration; Delayed-Action Preparations; Drug Evaluation; Goserelin; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms | 1987 |
Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
Topics: Aged; Aged, 80 and over; Buserelin; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Orchiectomy; Prostatic Neoplasms; Testis; Testosterone | 1987 |
Treatment of metastatic prostate carcinoma with the depot LRH analog Zoladex.
Topics: Adult; Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms; Ultrasonography | 1988 |
Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
Topics: Aged; Buserelin; Diethylstilbestrol; Drug Evaluation; Drug Therapy, Combination; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1988 |
Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Buserelin; Carcinoma; Drug Administration Schedule; Goserelin; Humans; Injections, Subcutaneous; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1988 |
Effect of long-acting LHRH analog (Zoladex) on prostate cancer: evaluated by transrectal ultrasonography.
Topics: Aged; Buserelin; Carcinoma; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Ultrasonography | 1988 |
Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Topics: Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Drug Administration Schedule; Estradiol; Estradiol Congeners; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone; Time Factors | 1988 |
Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
Topics: Buserelin; Diethylstilbestrol; Goserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1988 |
Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Topics: Aged; Aged, 80 and over; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1988 |
Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
Topics: Buserelin; Drug Evaluation; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Substance Withdrawal Syndrome; Testosterone | 1988 |
Long-term results of treating advanced prostatic cancer with the LH-RH analogue Zoladex.
Topics: Buserelin; Follow-Up Studies; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Pain; Prognosis; Prostatic Neoplasms; Testosterone; Time Factors | 1988 |
Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Buserelin; Carcinoma; Delayed-Action Preparations; Goserelin; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Remission Induction | 1988 |
LH-RH analogue treatment for advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Follow-Up Studies; Goserelin; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Remission Induction; Testosterone | 1988 |
Zoladex treatment of symptomatic prostatic carcinoma.
Topics: Buserelin; Carcinoma; Delayed-Action Preparations; Goserelin; Humans; Injections, Subcutaneous; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Remission Induction; Testosterone | 1988 |
Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Delayed-Action Preparations; Diethylstilbestrol; Follicle Stimulating Hormone; Goserelin; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Testosterone | 1988 |
Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Topics: Acid Phosphatase; Aged; Buserelin; Follicle Stimulating Hormone; Humans; In Vitro Techniques; Luteinizing Hormone; Male; Middle Aged; Prolactin; Prostatic Neoplasms; Receptors, Cell Surface; Receptors, FSH; Receptors, LH; Testis; Testosterone; Time Factors | 1985 |
LHRH agonists--mechanism of action and effect on target tissues.
Topics: Androgens; Animals; Buserelin; Follicle Stimulating Hormone; Luteinizing Hormone; Male; Pituitary Gland, Anterior; Progesterone; Prostatic Neoplasms; Rats; Receptors, Cell Surface; Receptors, LH; Receptors, LHRH; Testis; Testosterone | 1985 |
Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Topics: Androgen Antagonists; Animals; Buserelin; Diethylstilbestrol; Humans; Imidazoles; Imidazolidines; Kinetics; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Receptors, Androgen; Receptors, Cell Surface; Receptors, LHRH; Receptors, Steroid; Testosterone | 1986 |
Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
Topics: Acid Phosphatase; Aged; Animals; Buserelin; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Rats; Receptors, Cell Surface; Receptors, FSH; Receptors, LH; Receptors, LHRH; Receptors, Prolactin; Testis; Testosterone | 1986 |
Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome.
Topics: Buserelin; Climacteric; Follow-Up Studies; Humans; Libido; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; Time Factors | 1986 |
[Treatment of advanced prostate carcinoma with a depot form of an LH-RH analog: preliminary endocrinological and clinical results].
Topics: Acid Phosphatase; Aged; Buserelin; Delayed-Action Preparations; Drug Evaluation; Humans; Injections, Subcutaneous; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1986 |
[Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
Topics: Administration, Intranasal; Buserelin; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1986 |
Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.
Topics: Administration, Intranasal; Aged; Buserelin; Dihydrotestosterone; Drug Evaluation; Estradiol; Gonadal Steroid Hormones; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Random Allocation; Testis; Testosterone | 1986 |
Pre-treatment testosterone levels: significance in androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Buserelin; Carcinoma; Diethylstilbestrol; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Megestrol; Megestrol Acetate; Middle Aged; Orchiectomy; Prostatic Neoplasms; Testosterone | 1986 |
[Buserelin (Suprefact)].
Topics: Buserelin; Humans; Male; Prostatic Neoplasms | 1986 |
[Treatment of prostatic cancer with an LH-RH analog].
Topics: Aged; Aged, 80 and over; Buserelin; Carcinoma; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms | 1986 |
The first clinical use of depot buserelin for advanced prostatic carcinoma.
Topics: Aged; Buserelin; Delayed-Action Preparations; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1986 |
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Humans; Imidazoles; Imidazolidines; Lipoproteins, HDL; Male; Prostatic Neoplasms | 1987 |
Kinetic evaluation of the effect of LHRH analog on prostatic cancer using transrectal ultrasonotomography.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Buserelin; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Kinetics; Luteinizing Hormone; Male; Prostate; Prostatic Neoplasms; Testosterone; Ultrasonography | 1987 |
Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone analog, buserelin (HOE 766).
Topics: Adenocarcinoma; Aged; Buserelin; Humans; Lung; Lung Neoplasms; Male; Prostatic Neoplasms; Radiography | 1987 |
[Drug information. Drug treatment can now replace castration in prostatic cancer].
Topics: Antineoplastic Agents; Buserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1986 |
Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.
Topics: Adenocarcinoma; Aged; Buserelin; Follow-Up Studies; Humans; Male; Prostatic Neoplasms; Quality of Life | 1987 |
[Therapy of advanced prostate cancer].
Topics: Androgen Antagonists; Buserelin; Combined Modality Therapy; Estradiol Congeners; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms | 1987 |
Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Intranasal; Aged; Aged, 80 and over; Antineoplastic Agents; Buserelin; Drug Evaluation; Humans; Male; Middle Aged; Prostatic Neoplasms | 1987 |
Results of long term treatment of advanced prostatic cancer with the LHRH analogue buserelin.
Topics: Buserelin; Humans; Long-Term Care; Male; Prostatic Neoplasms | 1987 |
The effects of a gonadotropin-releasing hormone agonist on testicular histology.
Topics: Aged; Buserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Spermatogenesis; Testis | 1987 |
The Japanese experience: use of transrectal ultrasound in the evaluation of tumor response to various treatment modalities.
Topics: Animals; Buserelin; Carcinoma; Dogs; Estramustine; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Orchiectomy; Prostate; Prostatic Neoplasms; Testosterone; Ultrasonography | 1987 |
Hydroxyproline as a marker for following patients with metastatic prostate cancer.
Topics: Bone Neoplasms; Buserelin; Creatinine; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Hydroxyproline; Leuprolide; Male; Prostatic Neoplasms | 1988 |
Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy.
Topics: Adult; Aged; Biological Assay; Buserelin; Female; Follicle Stimulating Hormone; Granulosa Cells; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Radioimmunoassay | 1988 |
Pulmonary complications of hormone treatment in prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Pulmonary Fibrosis | 1988 |
The role of increased prolactin levels under GnRH analogue treatment in advanced prostatic carcinoma.
Topics: Buserelin; Humans; Male; Prognosis; Prolactin; Prostatic Neoplasms; Time Factors | 1988 |
New treatment modalities in prostatic cancer: LHRH superagonists. Symposium held during the World Congress of Oncology. Budapest, Hungary, August 26, 1986.
Topics: Buserelin; Humans; Male; Prostatic Neoplasms | 1988 |
[Treatment of advanced prostatic carcinoma with LHRH analogue].
Topics: Bone Neoplasms; Buserelin; Humans; Male; Pain; Prostatic Neoplasms; Urethral Obstruction | 1988 |
Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Topics: Aged; Buserelin; Delayed-Action Preparations; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1985 |
A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRH.
Topics: Buserelin; Delayed-Action Preparations; Drug Implants; Goserelin; Humans; Infusions, Parenteral; Kinetics; Male; Prostatic Neoplasms; Radioimmunoassay | 1985 |
Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
Topics: Breast Neoplasms; Buserelin; Female; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1985 |
Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
Topics: Animals; Buserelin; Delayed-Action Preparations; Female; Goserelin; Male; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Rats | 1985 |
Results obtained in the treatment of prostate cancer patients with Zoladex.
Topics: Buserelin; Goserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1985 |
Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
Topics: Administration, Intranasal; Buserelin; Dihydrotestosterone; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Injections, Intramuscular; Male; Prostatic Neoplasms; Testosterone; Time Factors; Triptorelin Pamoate | 1985 |
Management of metastatic prostatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Castration; Cyclophosphamide; Diethylstilbestrol; Estramustine; Gonadotropin-Releasing Hormone; Hormones; Humans; Leuprolide; Male; Neoplasm Metastasis; Prostatic Neoplasms | 1985 |
Prostate cancer: clinical trials of gonadotrophin-releasing hormone analogs as an alternative to orchiectomy.
Topics: Buserelin; Castration; Humans; Male; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms | 1985 |
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Topics: Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Radioimmunoassay; Testosterone; Time Factors; Triptorelin Pamoate | 1985 |
Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Topics: Acid Phosphatase; Aged; Buserelin; Drug Evaluation; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1985 |
A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
Topics: Buserelin; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Time Factors | 1985 |
Buserelin as primary therapy in advanced prostatic carcinoma.
Topics: Adult; Aged; Buserelin; Castration; Diethylstilbestrol; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms; Quality of Life; Testosterone | 1985 |
[What is safe in the therapy of advanced prostatic cancer?].
Topics: Androgen Antagonists; Antineoplastic Agents; Buserelin; Combined Modality Therapy; Estradiol Congeners; Estramustine; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Lymphatic Metastasis; Male; Neoplasm Staging; Orchiectomy; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms | 1985 |